Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 15 min ago

Pharmacology & toxicology

3,013 studies233 in 7 days1,447 in 30 days

Filters
Type
Date
Clear

Latest

3,013 studies

  1. Five-year trends in hospital extemporaneous compounding prescriptions in Thailand: A real-world study
    Chonladda Pitchayajittipong, Thanatcha Songmuang, Kittithara Khlangvicha +3
    Journal of Pharmacy & Pharmacognosy ResearchPeer-reviewedCC BY-NC-NDFull textPharmacology & toxicologyDOAJ
  2. Evaluation of Therapeutic Drug Monitoring for Vancomycin with Ratio of Area Under the Curve to Minimum Inhibitory Concentration at a Children’s and Women’s Tertiary Hospital
    Alyssa Azote, Roxane Carr, Kaitlin McDougal +2
    The Canadian Journal of Hospital PharmacyPeer-reviewedLicence not statedFull textPharmacology & toxicologyPMC
  3. Liver-targeted drug delivery systems of traditional Chinese medicine: a novel strategy for the treatment of fatty liver disease
    Letao Zhao, Yongji Li, Jinjin Dou +5
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  4. Pretreatment with Commelina communis L. improves survival following influenza a virus infection and enhances innate interferon signaling
    Eun-Bin Kwon, Hye Jin Yang, Buyun Kim +4
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  5. Drug repurposing and treatment optimisation in oncology: regulatory challenges and policy priorities
    Gincy George, Harriet Wylie, Danielle Crawley +5
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  6. Roxadustat ameliorates bone microarchitectural deterioration in CKD-MBD rats in association with mitigated systemic micro-inflammation and restored FGF23–Wnt/β-catenin signaling
    Zhenzhen Shan, Yan Liu, Xue Sun +6
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  7. Beyond classical synthetic lethality: how PARP inhibitor pharmacology contributes to antitumor activity in HR-proficient cancers
    Yan Han, Mengqi Li, Yuting Su +4
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  8. Acid-sensing ion channels in pain and psychiatric disorders: from basic properties to comorbidity mechanisms
    Congcong Li, Lei Ye, Shuna Qin +6
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  9. A literature-informed pharmacokinetic framework for polymyxin B dosing during continuous renal replacement therapy: integrating renal function and extracorporeal clearance
    Aoao Pei, Tingting Wu, Jingjing Liu +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  10. Effects of an optimized beta-glucan–based formulation on symptoms, functional capacity, and systemic inflammation in patients with COPD: a randomized controlled trial
    Supamas Napavichayanun, Rungnapha Yamdech, Sarocha Cherdchom +4
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  11. Molecular mechanisms of plant-derived saponins against ulcerative colitis: a narrative review
    Chuncheng Qu, Bo Wang, Hang Su +3
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefDOAJ
  12. Intratracheal Administration of Benzbromarone Attenuates Pulmonary Vascular Remodeling and Improves Survival in Rats with Monocrotaline-Induced Pulmonary Hypertension
    Yukari Hikawa, Koya Nakahama, Aya Yamamura +3
    Biological and Pharmaceutical BulletinPeer-reviewedCC BY-NCFull textPharmacology & toxicologyJ-STAGE
  13. Case Report: Third-line QL1706, a bifunctional PD-1/CTLA-4 MabPair product, plus chemotherapy for primary small-cell neuroendocrine carcinoma of the ureter
    Xiaomin Li, Zhe Meng, Yao Liu +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyFrontiersCrossrefDOAJ
  14. Pathological complete response and major pathological response as surrogate endpoints for recurrence-free survival in perioperative immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis
    Xin Ai, Xiaoxiao Wang, Xin Wang +4
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  15. Beyond class assumptions: a clinical decision framework for navigating drug-supplement interactions in oncology
    Candy Tsourounis
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyFrontiersCrossrefDOAJ
  16. Plant-derived extracellular vesicles in musculoskeletal disorders: a narrative review of mechanisms, therapeutic efficacy, and translational prospects
    Qixuan Jiang, Lei Chen, Junyan Li +7
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  17. Unraveling the molecular basis of ADC-related interstitial lung disease: from structural determinants to pathogenic pathways and mitigation strategies
    Yige Wang, Qiang Xiao
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  18. Single-cell and spatial omics in urologic cancer immunotherapy: bibliometric and registry mapping with an exploratory full-text assessment
    Danhong Zhou, Junhua Li, Chenhao Tang +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  19. Inter-organ interaction axes in systemic inflammation: network pathological mechanisms, pharmacological targets, and precision treatment strategies
    Shuangbin Xie, Haoran Tian, Yanjuan Song +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  20. Ginseng-Sanqi-Chuanxiong extract ameliorates hypertensive vascular aging through endothelial–smooth muscle cell crosstalk via the PPARγ/NF-κB axis
    Meiyu Cui, Xiaohui Yuan, Yingkun Fu +6
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  21. Endpoint design in pulmonary arterial hypertension therapeutic trials permitting pediatric enrollment: a ClinicalTrials.gov registry analysis
    Xiaolan Zheng, Yimin Hua
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  22. Translational pharmacology of (+)-terrein: from biological activity to oral and periodontal therapeutic development
    Kazuhiro Omori, Hiroki Mandai, Masaaki Nakayama +5
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  23. Anlotinib suppresses homologous recombination via the E2F8-RAD51 axis to activate STING immunity and potentiate PARP inhibitor synthetic lethality in resistant small cell lung cancer
    Wenjun Shao, Peiyan Zhao, Yang Tan +4
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  24. Lidocaine modulates interleukin-1β and interferon-α2 secretion in LPS with ATP stimulated human peripheral blood mononuclear cells
    Cees-Jan Oostwouder, Karin Vos, Mathijs R. Merkus +8
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  25. Epoxy fatty acids reduce corneal opacity and myofibroblast activation after alkali injury
    Xiaowen Lu, Christophe Morisseau, Zhong Chen +5
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref